NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View
Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 ...
Pharmaceutical Technology9d
Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals
The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...
FiercePharma15d
Novo Nordisk hit with FDA write-up over production issues at critical semaglutide plant
Novo's spokesperson said the issues around the insulin product—approved in places like Canada, Europe and Japan as Awiqli—are unlikely to be resolved this year. Fire breaks out at Novo ...
pharmaphorum4d
FDA rejects Novo Nordisk’s weekly basal insulin
Awiqli has been cleared for both types of diabetes in all its current markets except China, where it can be used for type 2 only. “We believe in the potential of once-weekly basal insulin icodec ...
pharmaphorum25d
CHMP backs Novartis’ Fabhalta as first oral therapy for PNH
Once-weekly insulin, and a new antibiotic Other highlights of the meeting included a positive opinion for Novo Nordisk’s Awiqli (insulin icodec) for adults with type 1 and 2 diabetes ...